Comparison of vaginal hysterectomy and laparoscopic hysterectomy: a systematic review and meta-analysis.

We selected RCTs that compared VH with LH (LAVH or TLH or unspecified LH) published from January 2000. No language restriction was used. We included women who underwent VH and LH for benign gynaecological indications and excluded women with gynaecological malignancies. The primary outcome of the present analysis was the incidence of intraoperative and postoperative complications. Operative complications were classified by the Dindo classification of surgical complications [ 6 ]. Secondary outcomes were operating time, blood loss, rate of conversion to laparotomy, postoperative pain, length of hospital stay and length of recuperation. This meta-analysis was prepared in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA Statement) [ 7 , 8 ]. A literature search for articles published from 1 January 2000 to present was conducted within the main international databases. We searched records from the following databases: Medline, EMBASE, and CENTRAL (The Cochrane Library) for combinations of the terms “hysterectomy,” “laparoscop*,” “vagina*,” “laparoscop*” AND assisted AND vagina*,“and” “benign AND condition*” OR indication* OR disease* OR “disorder*”. Symbol * was used for truncation. The studies were included after fulfilling the following inclusion criteria: RCTs; hysterectomy performed for benign gynaecological conditions, and VH outcomes compared with those of any LH. Studies were excluded from the analysis if any one of the inclusion criteria was not met. Two reviewers (SR Oh and SH Lee) independently reviewed the articles and extracted the data. Disagreements were resolved by the other reviewers (JH Yoon, SE Choi). Two reviewers (SR Oh and SH Lee) worked independently and examined the potential eligibility of all the studies retrieved from the database after fulfilling the inclusion and exclusion criteria. Next, they extracted and assessed the risk of bias in each full text article. The other reviewers (JH Yoon, SE Choi) resolved inconsistencies between the first two reviewers through consensus of the whole research team. First reviewers extracted data from the included studies. The data was confirmed twice by the second reviewers to minimize potential errors. Conflicts were resolved by consensus and discussion. The data extracted from each study included the author, publication year, type of study, number of patients, routes of hysterectomy (VH, LAVH, TLH and unspecified LH), and outcomes (complications, operating time, blood loss, intraoperative conversion, postoperative pain, length of hospital stay and length of recuperation). We first tried to extract numerical data from tables, text or figures. If these data were not reported numerically, we extracted data from graphs using digital ruler software. When summary data included only the median and range, data were transformed according to the methods described by Hozo et al. [ 9 ]. We used tools for assessing quality and risk of bias from the Cochrane Handbook for Systematic Reviews of Interventions to evaluate the methodological quality of RCTs [ 10 ]. The following seven items were evaluated: Random sequence generation Allocation concealment Blinding of participants and personnel Blinding of outcome assessment Incomplete outcome data Selective reporting Other bias Random sequence generation Allocation concealment Blinding of participants and personnel Blinding of outcome assessment Incomplete outcome data Selective reporting Other bias The answers for each item included “low” (low risk of bias), “unclear” (either lack of information or uncertainty over the potential for bias), or “high” (high risk of bias). Pairs of independent reviewers assessed the methodological quality. Discrepancies were resolved by consensus of the whole team. A meta-analysis was conducted using Review Manager version 5.3 software, which was designed for and used in Cochrane reviews. Random-effects models were used to calculate a pooled estimate of effect in the meta-analysis. The dichotomous outcomes of each study are represented as the risk ratio (RR) with an estimated 95% confidence interval (CI). The continuous variables are shown as the weighted mean difference (WMD) with 95% CI, which were calculated from the mean, standard deviation (SD), p -value, and sample size of each study. Heterogeneity was assessed using Higgins I 2 value that evaluates the percentage of total variation across a study due to heterogeneity rather than by chance alone: low heterogeneity (I 2   75%). We used GRADEpro GTD web-based software to rate the quality of each outcome according to GRADE guidelines [ 11 – 13 ].

The primary search retrieved 1611 citations with combinations of the terms “hysterectomy”, “laparoscop*”, “vagina*”, “laparoscop* AND assisted AND vagina*” and “benign AND condition* OR indication* OR disease* OR disorder*”, which were screened for eligible studies. After excluding duplicate citations, 1041 potentially eligible citations were identified and examined in detail. Of these, 1023 articles were excluded because of the inclusion of only one surgical approach (VH or TLH or LAVH), non-RCT design or inclusion of patients with malignancies. Eighteen articles reporting results from RCTs comparing VH ( n  = 677) with LH ( n  = 941) were included in the present meta-analysis (Fig.  1 ). The meta-analysis was performed using Review Manager, and the studies comparing VH and LH were divided into three subgroups: VH vs. LAVH; VH vs. TLH; and VH vs. unspecified LH. Hence, the number of studies on VH was duplicated in each outcome. The risks of bias in the included studies are summarised in Fig.  2 . Fig. 1 PRISMA flow diagram of the study screening and selection process Fig. 2 Risk of bias summary. Green circle (low risk), yellow circle (unclear), red circle (high risk) PRISMA flow diagram of the study screening and selection process Risk of bias summary. Green circle (low risk), yellow circle (unclear), red circle (high risk) Table  1 details the inclusion and exclusion criteria for the 18 studies included in this meta-analysis. Two of the studies specified inclusion of hysterectomy for benign uterine diseases only, and 12 studies included benign uterine diseases and limit of uterine or myoma size. Three studies included benign uterine diseases and possible VH. One included myoma size larger than 8 cm. Four of the included trials excluded women with pelvic organ prolapse (POP) beyond stage I, and eight studies excluded women with pelvic inflammatory disease, endometriosis and/or previous uterine surgeries. Table 1 Characteristics of included studies First author, year Type of study Method Number of patients Inclusion criteria Exclusion criteria Outcomes Risk of bias according to Cochrane risk of bias tools Agostini, 2006 RCT LAVH vs. VH 48 Benign uterine diseases, uterine size below pubis, favorable to BSO † Adnexal mass Operative data, complications high Allam, 2015 RCT TAH vs.TLH vs. VH 60 Benign uterine diseases Malignancy Operative data, complications unclear Candiani, 2009 RCT TLH vs. VH 47 Benign uterine diseases Malignancy, estimated uterine volume > 300 mL, POP ‡ , ovarian pathology, PID § , endometriosis Operative data, complications high Darai, 2001 RCT LAVH vs. VH 80 Estimated uterine size > 280 g, contraindications to VH Malignancy Operative data, complications high Drahonovsky, 2010 RCT LAVH vs. TLH vs. VH 125 Benign uterine diseases Impossible VH, prior abdominal surgery, endometriosis, medical disorders Operative data, complications high Eggemann, 2018 RCT LAVH vs. VH 192 Benign uterine diseases, possible VH Malignancy, POP ‡ , medical disorders Operative data, complications high Garry, 2014 RCT Unspecified LH vs. VH 504 Benign uterine diseases Malignancy, POP ‡ , uterine size > 12 week gestation Operative data, complications high Ghezzi, 2010 RCT TLH vs. VH 82 Benign uterine diseases Malignancy, POP ‡ , uterine size > 14 week gestation, large adnexal mass Operative data, complications high Hwang, 2002 RCT LAVH, vs. TAH vs. VH 60 Myoma > 8 cm other benign gynecological conditions except myoma Operative data, complications high Mohammed, 2017 RCT LAVH vs. VH 50 Benign uterine diseases, age (40–70 years), estimated uterine weight  30, endometriosis, previous myomectomy, medical disorder Operative data, complications unclear Ottosen, 2000 RCT LAVH vs. TAH vs. VH 80 Benign uterine disease, myoma  16 week gestation, ovarian pathology, dense pelvic adhesion, possible VH Operative data, complications high Ribeiro, 2003 RCT TAH vs. TLH vs. VH 40 Benign uterine diseases Estimated uterine volume > 400 cm 3 , medical disorders Operative data, complications, inflammatory response high Roy, 2011 RCT LAVH vs. TLH vs. VH 90 Benign uterine diseases, estimated uterine weight  280 g, contraindications to VH Malignancy Operative data, complications high Sesti, 2014 RCT LAVH vs. TLH vs. VH 108 Symptomatic myoma, age  12 week gestation Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, Operative data, complications low Sesti, 2008 RCT LAVH vs. TLH vs. VH 100 Symptomatic myoma, age  12 week gestation Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, Operative data, complication unclear Sesti, 2008 RCT LAVH vs. VH 80 Symptomatic myoma, age  12 week gestation Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, Operative data, complication unclear Zhu, 2009 RCT LAVH vs. VH 69 Benign uterine diseases Malignancy Operative data, complication high † Bilateral salpingo-oophorectomy ‡ Pelvic organ prolapse § Pelvic inflammatory disease Characteristics of included studies † Bilateral salpingo-oophorectomy ‡ Pelvic organ prolapse § Pelvic inflammatory disease Seventeen trials reported incidences of perioperative complications [ 5 , 14 – 29 ], which were classified by Dindo classification (grade I to V) [ 6 ]. No difference in the rate of overall complications was found between VH and LH (RR 1.11, 95% CI; 0.85 to 1.45, p  = 0.46). There was also low heterogeneity (I 2  = 25%) (Fig.  3 ). Table  2 summarises all the complications in the included studies. Grade I complications were fever, vault hoematoma, urinary tract infection, vaginal bleeding, urinary retention and unspecified infections. No significant differences in the incidence of grade I complications were demonstrated between VH and LH (RR 1.20, 95% CI; 0.90 to 1.61, p  = 0.22), and there was low heterogeneity (I 2  = 19%) (Fig. 3 ). Most of the grade II complications was transfusion ( n  = 82). One patient in the VH group was treated with heparin because of deep vein thrombosis and experienced a spontaneous resolution. No significant difference in the incidence of grade II complications was demonstrated between VH and LH (RR 0.78, 95% CI; 0.49 to 1.24, p  = 0.30), and there was low heterogeneity (I 2  = 0%) (Fig.  4 ). Grade III complications included those requiring surgical, endoscopic, or radiological intervention. There was one ureteral injury, seven bladder injuries and two reoperations in the VH group and eight bladder injuries, one vesicovaginal fistula, one ureterovaginal fistula, one reoperation and two pulmonary embolisms in the LH group. No significant difference in the incidence of grade III complications was demonstrated between VH and LH (RR 1.03, 95% CI; 0.49 to 2.16, p  = 0.94), and there was low heterogeneity (I 2  = 0%) (Fig. 4 ). No significant difference in the incidence of urinary tract injury was demonstrated between VH and LH (RR 1.19, 95% CI; 0.52 to 2.71, p  = 0.68), and there was low heterogeneity (I 2  = 0%). None of the trials included in the present analysis reported any grade IV or V complications after either VH or LH. Fig. 3 Forest plots of overall ( a ) and grade I ( b ) complications Table 2 Complications by surgical approach First author, year VH(n) Overall complications Grade I complications Grade II complications Grade III complications LH(n) Overall complications Grade I complications Grade II complications Grade III complications Agostini, 2006 24 1 Vault hematoma [ 1 ] 0 0 24 3 Fever [ 1 ], vault hematoma [ 2 ] 0 0 Allam, 2015 30 9 Vault hematoma [ 2 ] Transfusion [ 6 ] Ureteral injury [ 1 ] 30 1 0 Transfusion [ 1 ] 0 Candiani, 2009 30 6 Fever [ 5 ] DVT † [ 1 ] 0 30 3 Fever [ 3 ] Darai, 2001 40 5 Fever [ 2 ], infection [ 1 ], vault hematoma [ 1 ] Transfusion [ 1 ] 0 40 9 Fever [ 3 ], infection [ 3 ], vault hematoma [ 1 ] Transfusion [ 1 ] Cystotomy [ 1 ] Drahonovsky, 2010 40 20 Fever [ 8 ], vault hematoma [ 10 ] Transfusion [ 1 ] Cystotomy [ 1 ] 85 25 Fever [ 4 ], UTI ‡ [ 3 ], vault dehiscence [ 5 ], vault hematoma [ 9 ] Transfusion [ 1 ] Cystotomy [ 1 ] UVF § [ 1 ] VVF §§ [ 1 ] Eggemann, 2018 97 3 Fever [ 1 ] Transfusion [ 1 ] Cystotomy [ 1 ] 95 3 Fever [ 1 ] Transfusion [ 1 ] Cystotomy [ 1 ] Garry, 2004 168 65 Anesthetic problem [ 1 ], fever [ 12 ], infection [ 24 ], vaginal bleeding [ 2 ], vault hematoma [ 10 ] Transfusion [ 14 ] Cystotomy [ 2 ] 336 123 Anesthetic problem [ 3 ], fever [ 18 ], infection [ 36 ], vaginal bleeding [ 8 ], vault hematoma [ 14 ] Transfusion (39) Cystotomy [ 3 ] Pulmonary embolism [ 2 ] Ghezzi, 2010 41 4 Fever [ 2 ], urinary retention [ 2 ] 0 0 41 1 Urinary retention [ 1 ] 0 0 Hwang, 2002 30 5 Fever [ 4 ] Transfusion [ 1 ] 0 30 6 UTI ‡ [ 1 ] Transfusion [ 5 ] 0 Mohammed, 2017 25 4 0 Transfusion [ 2 ] Cystotomy [ 2 ] 25 6 0 Transfusion [ 4 ] Cystotomy [ 2 ] Ottosen, 2000 40 7 Fever [ 1 ], UTI ‡ [ 1 ], vault infection [ 1 ], vault hematoma [ 1 ] 0 Reoperation [ 2 ], cystotomy [ 1 ] 40 4 Fever [ 1 ], urinary retention [ 1 ], vault infection [ 1 ] 0 Reoperation [ 1 ] Ribeiro, 2003 20 1 0 0 Cystotomy [ 1 ] 20 0 0 0 0 Roy, 2011 30 8 Fever [ 4 ], vaginal bleeding [ 4 ] 0 0 60 22 Fever [ 10 ], UTI ‡ [ 4 ], vaginal bleeding [ 6 ], wound infection [ 2 ] 0 0 Sesti, 2014 36 1 Fever [ 1 ] 0 0 72 5 Fever [ 2 ], urinary retention [ 1 ] Transfusion [ 2 ] 0 Soriano, 2001 35 1 0 Transfusion [ 1 ] 0 37 1 0 Transfusion [ 1 ] 0 † Deep vein thrombosis ‡ Urinary tract infection § Ureterovaginal fistula §§ Vesicovaginal fistula Fig. 4 Forest plots of grade II ( a ) and grade III ( b ) complications Forest plots of overall ( a ) and grade I ( b ) complications Complications by surgical approach Fever [ 8 ], vault hematoma [ 10 ] Fever [ 4 ], UTI ‡ [ 3 ], vault dehiscence [ 5 ], vault hematoma [ 9 ] Cystotomy [ 1 ] UVF § [ 1 ] VVF §§ [ 1 ] Cystotomy [ 3 ] Pulmonary embolism [ 2 ] Fever [ 2 ], urinary retention [ 2 ] Fever [ 4 ], vaginal bleeding [ 4 ] Fever [ 10 ], UTI ‡ [ 4 ], vaginal bleeding [ 6 ], wound infection [ 2 ] † Deep vein thrombosis ‡ Urinary tract infection § Ureterovaginal fistula §§ Vesicovaginal fistula Forest plots of grade II ( a ) and grade III ( b ) complications Secondary outcomes were operating time, blood loss, intraoperative conversion, postoperative pain, length of hospital stay and length of recuperation. Eighteen studies reported on operating time [ 5 , 14 – 18 , 20 – 31 ]. VH was associated with a shorter operating time than LH (WMD − 34.01 min, 95% CI; − 43.54 to − 24.48 min, p  < .0001) (Fig.  5 ), and there was high heterogeneity between the trials (I 2  = 98%). However, all studies except one favored VH [ 31 ]; thus, the risk of inconsistency for this outcome was not severe. There was no difference in blood loss between VH and LH (WMD − 35.91 mL, 95% CI; − 102.26 to 30.43 mL, p  = 0.29) in 12 studies [ 5 , 14 , 17 , 21 – 29 ]. There was high heterogeneity (I 2  = 97%) between trials. Twelve studies assessed intraoperative conversion [ 14 , 17 – 19 , 21 , 23 – 29 ]. No difference was found between VH and LH (RR 1.16, 95% CI; 0.60 to 2.26, p  = 0.66), and there was low heterogeneity (I 2  = 0%). Postoperative pain scores were evaluated using the visual analog scale (VAS) on the day of surgery in four studies [ 5 , 19 , 27 , 29 ], at 24 h after surgery in three studies [ 5 , 17 , 29 ] and at 48 h after surgery in three studies [ 5 , 19 , 29 ]. VH was associated with significantly lower VAS pain scores than LH at 24 h after surgery (WMD -0.53, 95% CI; − 0.70 to − 0.35, p  < .0001, I 2  = 0%), with low heterogeneity (Fig. 4 ). There was no difference between the two groups on the day of surgery (WMD 0.80, 95% CI; − 0.08 to 1.68, p  = 0.07) and at 48 h after surgery (WMD -0.20, 95% CI; − 0.61 to 0.22, p  = 0.35). Eleven studies reported on the length of hospital stay [ 14 , 17 , 19 , 21 – 28 ]. There was no difference in the length of hospital stay between VH and LH (WMD − 6.57 h, 95% CI; − 18.65 to 5.50 h, p  = 0.29), and there was high heterogeneity (I 2  = 99%). Three studies assessed the duration of recuperation [ 14 , 17 , 25 ]. A difference in the recuperation time between VH and LH was not found (WMD 0.65 days, 95% CI; − 6.01 to 7.30 days, p  = 0.85), and there was high heterogeneity (I 2  = 92%). Fig. 5 Forest plot of operating time Forest plot of operating time We used the GRADEpro GTD web-based software to rate the quality of each outcome according to GRADE guidelines, and the results are summarized in Table  3 . Table 3 Rating of quality of evidence with GRADE system Certainty assessment Number of patients Effect Certainty Importance Number of studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations LH VH Relative (95% CI) Absolute (95% CI) Overall complications 17 randomised trials serious† not serious not serious not serious none 169/887 (19.1%) 212/1055 (20.1%) RR 1.11 (0.85 to 1.45) 22 more per 1000 (from 30 fewer to 90 more) ⨁⨁⨁◯ MODERATE none Grade I complications 17 randomised trials serious† not serious not serious not serious none 128/887 (14.4%) 144/1055 (13.6%) RR 1.20 (0.90 to 1.61) 27 more per 1000 (from 14 fewer to 83 more) ⨁⨁⨁◯ MODERATE none Grade II complications 17 randomised trials serious† not serious not serious not serious none 29/887 (3.3%) 55/1055 (5.2%) RR 0.78 (0.49 to 1.24) 11 fewer per 1000 (from 13 more to 27 fewer) ⨁⨁⨁◯ MODERATE none Grade III complications 17 randomised trials serious† not serious not serious not serious none 12/887 (1.4%) 14/1055 (1.3%) RR 1.03 (0.49 to 2.16) 0 fewer per 1000 (from 7 fewer to 15 more) ⨁⨁⨁◯ MODERATE none Urinary tract injuries 17 randomised trials serious† not serious not serious not serious none 9/781 (1.2%) 10/1020 (1.0%) RR 1.20 (0.50 to 2.85) 2 more per 1000 (from 5 fewer to 18 more) ⨁⨁⨁◯ MODERATE none Operating time 18 randomised trials serious† not serious not serious not serious none 922 1089 – MD 34.01 h lower (45.54 lower to 24.48 lower) ⨁⨁⨁◯ MODERATE none Length of hospital stay 14 randomised trials serious‡ serious§ c not serious not serious none 636 809 – MD 6.57 h lower (18.65 lower to 5.5 higher) ⨁⨁◯◯ LOW none Blood loss 16 randomised trials serious† serious§ not serious not serious none 595 598 – MD 35.91 mL lower (102.26 lower to 30.43 higher) ⨁⨁◯◯ LOW none Intraoperative conversion 7 randomised trials serious† not serious not serious not serious none 15/771 (1.9%) 24/939 (2.6%) RR 0.94 (0.49 to 1.81) 2 fewer per 1000 (from 13 fewer to 21 more) ⨁⨁⨁◯ MODERATE none Recuperation 4 randomised trials serious‡ serious§ not serious not serious none 130 130 – MD 0.66 days higher (0.77 lower to 0.9 higher) ⨁⨁◯◯ LOW none Pain on day of surgery (assessed with: Visual analogue scale) 5 randomised trials serious† not serious not serious not serious none 325 491 – MD 0.8 higher (0.08 lower to 1.68 higher) ⨁⨁⨁◯ MODERATE none Pain at 24 h after surgery (assessed with: Visual analogue scale) 4 randomised trials serious† not serious not serious not serious none 155 157 – MD 0.53 lower (0.7 lower to 0.35 lower) ⨁⨁⨁◯ MODERATE none Pain at 48 h after surgery (assessed with: Visual analogue scale) 4 randomised trials serious† not serious not serious not serious none 295 461 – MD 0.2 lower (0.61 lower to 0.22 higher) ⨁⨁⨁◯ MODERATE none CI Confidence interval, RR risk ratio, and MD mean difference † High risk of allocation and blinding ‡ High risk of blinding and incomplete outcome data § High heterogeneity Rating of quality of evidence with GRADE system CI Confidence interval, RR risk ratio, and MD mean difference † High risk of allocation and blinding ‡ High risk of blinding and incomplete outcome data § High heterogeneity

The results of this study suggest that VH should be the treatment of benign gynecologic disease when both operative methods are available. Large randomized controlled trials should be performed to identify differences in VH and LH outcomes for operation time, postoperative pain, perioperative complications and cost.

The surgical approach of hysterectomy is the most important factor responsible for postoperative morbidity. Many studies have compared the surgical approach and complications according to the type of surgery to determine which method is best for the patient. The conclusion suggests that abdominal hysterectomy is inferior to VH and LH [ 32 ]. There were few randomized trials comparing VH and LH for postoperative complications, operative time, hospital stay, and recovery. The results of our meta-analysis showed no difference between the two groups for the overall rate of complications, including grade I, II and III complications of intraoperative blood loss, intraoperative conversion, length of hospital stay and length of recuperation after surgery. VH was associated with a shorter operative time and less pain at 24 h after surgery than LH. An important matter of concern about LH is a higher incidence of urinary tract injuries [ 33 ]. Our meta-analysis showed no significant difference in urinary tract injuries between VH and LH (10 of 887 vs. 10 of 1055; p  = 0.68). A recent study of 839 women undergoing hysterectomy for benign indications reported that the incidence of urinary tract injuries was 4.3%, including an incidence of 2.9% for bladder injury and 1.8% for ureteral injury [ 34 ]. One review article reported that the incidence of ureteral injury is estimated to be 0.03 to 2% for AH, 0.02 to 0.5% for VH and 0.2 to 6% for LH [ 35 ]. In this meta-analysis, we found that the incidence of urinary tract injuries was 1.02%. Hence, the incidence of ureteral injury was unlikely to be underreported in the included studies. Interestingly, we found two fistula formations following TLH but no fistula formations following VH. During TLH, many surgeons use electrical laparoscopic instruments to cauterize the uterine artery and dissect the vesicouterine fold; the incidence of fistula formation might thus increase as a consequence of thermal injury [ 36 ]. A Cochrane review in 2015 concluded that VH appears to be superior to LH for benign indications, as VH is associated with a faster return to normal activities than LH according to a meta-analysis including two studies of 140 patients [ 14 , 17 ], and there were no advantages of LH over VH, as the operation time was longer for LH and the incidence of urinary tract injuries was greater for TLH than for VH [ 32 ]. Comparing our meta-analysis including four additional RCTs with 440 patients (VH vs. LH) to Cochrane review in 2015, the operation time of VH was significantly faster than that of LH similarly but we found no difference between the two groups in the time to return to normal activities, incidence of urinary tract injury and length of hospital stay. Furthermore, VH was associated with reduced pain scores at 24 h after surgery. The more postoperative pain in LAVH in our study might be caused by the pneumoperitoneum, the pain caused by traction of uterus and the abdominal incisions for the ports [ 24 ]. One study concluded that LH was the least cost-effective due to the expensive laparoscopic devices and long operation time [ 37 ]. The operation time of LH has shortened over the last couple decades. However, the cost of disposable laparoscopic devices is inevitably more expensive than that of the conventional surgical instruments used in VH. Gynaecologists around the world should focus on the effect of the rapid development of LH on the treatment of benign indications, especially VH training and skills among residents. When deciding the route of hysterectomy, the preference and proficiency of the surgeon may be the most decisive factors. As a result, if LH is performed more often than VH, gynaecologists in the future will be unfamiliar with VH, leading to a more profound decrease in the implementation of VH. Despite evidence supporting benefits of VH, current statistics indicate VH is underutilised in treating benign gynaecologic conditions [ 4 ]. The decreased utilisation of VH is undesirable because VH is the least invasive approach, shorter operating time and less cost than other types of hysterectomy from an evidence-based viewpoint. Main causes associated with decreased utilisation of VH include changes of resident training in surgical techniques due to the tremendous developments of laparoscopic skills and devices, changes of surgical skills in practice, attention to alternative hysterectomy techniques, and enormous propaganda effects of laparoscopic device companies. To increase the rate of VH as the primary approach in possible cases, teaching hospitals around the world should try to increase utilisation of VH on purpose for increasing familiarity with VH during resident training. According to our review, if both procedures are technically feasible, VH exhibits advantages in the operating time, which can be one of the most important factors for reducing hospital cost. All of hysterectomy cannot be performed by VH, but all of hysterectomy should not be performed laparoscopically. The limitation of our study is that all included studies had a high risk of bias in blinding despite the RCT design. Hence, no outcome had high-quality evidence according to the GRADE methodology. However, given that our primary outcome was the comparison of complication risk between the two groups, outcomes such as overall complications, grade 3 complications and risk of urinary tract injuries had moderate-quality evidence. Additional large-scale, multicenter, long-term randomized trials including objective outcome assessment will be required to definitively establish the value of LH vs VH.

A substantial number of women undergo hysterectomy annually, and 70 % of hysterectomies are performed for benign indications, including leiomyoma, adenomyosis, severe dysmenorrhea and uterine prolapse [ 1 ]. The surgical approach of hysterectomy is the most important factor responsible for postoperative morbidity. Until the present, the approaches for hysterectomies are vaginal, abdominal, laparoscopic and robotic assisted laparoscopic hysterectomy. If feasible, vaginal hysterectomy is associated with a shorter duration of hospital stay, speedier recuperation, fewer unspecified infections or febrile episodes than abdominal hysterectomy [ 2 ]. Since Reich first performed laparoscopic hysterectomy (LH) in 1989, various laparoscopic techniques and instruments have been developed, resulting in the vigorous implementation of LH, including laparoscopic-assisted vaginal hysterectomy (LAVH) and total laparoscopic hysterectomy (TLH) at present [ 3 ]. In contrast, VH is commonly utilized to treat uterine prolapse, but despite proven safety and effectiveness, it remains underutilized for the surgical treatment of non-prolapse conditions [ 4 ]. Gynaecologists perform LAVH or TLH according to their preference, and it is conservative to say that gynaecologists performing LH almost never perform VH [ 4 ]. There are several reasons for the widespread implementation of LH. First, LH can facilitate a better anatomical view, which has advantages over VH in cases of severe endometriosis or when there is a history of pelvic inflammatory disease. Second, in cases of large uterine size and for uteruses with little or no descent, LH simplifies the separation of the uterus from its attachment to the pelvic wall [ 5 ]. There are multiple approaches to hysterectomy, and each method has its procedure-specific advantages and disadvantages. Since VH and LH are minimally invasive techniques for benign indications that are widely performed around the world, we present a meta-analysis of randomised controlled trials (RCTs) comparing LH with VH for benign gynaecological conditions to identify which surgical approach is superior with respect to various surgical outcomes, especially the rates of complications.

Additional file 1: The raw data of the enrolled studies. (XLSX 12 kb) The raw data of the enrolled studies. (XLSX 12 kb)